Cumulative gadodiamide administration leads to brain gadolinium deposition in early MS
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received April 21, 2018
- Accepted in final form April 2, 2019
- First Published July 8, 2019.
Article Versions
- Previous version (July 8, 2019 - 12:45).
- You are viewing the most recent version of this article.
Author Disclosures
- Robert Zivadinov, MD, PhD,
- Niels Bergsland, PhD,
- Jesper Hagemeier, PhD,
- Deepa P. Ramasamy, MD,
- Michael G. Dwyer, PhD,
- Ferdinand Schweser, PhD,
- Channa Kolb, MD,
- Bianca Weinstock-Guttman, MD and
- David Hojnacki, MD
- Robert Zivadinov, MD, PhD,
R Zivadinov received personal compensation from Genzyme-Sanofi, Celgene and Novartis for serving on scientific advisory board.
NONE
R Zivadinov received personal compensation from EMD Serono, Inc., Novartis, Sanofi-Genzyme,Celgene for speaking
NONE
NONE
NONE
NONE
R Zivadinov received personal compensation from EMD Serono, Inc., Novartis, Sanofi-Genzyme for consulting fees.
R Zivadinov received personal compensation from EMD Serono, Inc., Novartis, Sanofi-Genzyme for speaking
NONE
NONE
Dr. Zivadinov: financial support for research activities from EMD Serono, Inc., Novartis, Sanofi-Genzyme,Mapi Pharma, Celgene and Protembis.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Niels Bergsland, PhD,
NONE
NONE
NONE
1) Journal of Neuroimaging, Editorial board member, 2018-present 2) PLOS ONE, Academic Editor, 2018-present 3) Journal of Magnetic Resonance Imaging, Associate Editor, 2018-present
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jesper Hagemeier, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Deepa P. Ramasamy, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Michael G. Dwyer, PhD,
(1) Claret Medical
NONE
NONE
Assistant Editor, Journal of Neuroimaging
NONE
NONE
NONE
(1) Claret Medical, Inc. (2) EMD Serono
NONE
NONE
NONE
(1) Novartis (2) Celgene
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ferdinand Schweser, PhD,
NONE
NONE
(1) Toshiba Canada Medical Systems Limited, Speaker Honoraria (2) Toshiba Canada Medical Systems Limited, Travel (3) SynchroPET Inc., Travel (4) GE Healthcare, Travel
NONE
NONE
NONE
NONE
(1) Goodwin Procter LLP
NONE
NONE
NONE
(1) SynchroPET Inc. (2) Canon Medical Systems Corporation (3) Canon Medical Research USA, Inc.
NONE
NONE
(1) Dana Foundation
NONE
NONE
NONE
NONE
NONE
(1) Goodwin Procter LLP, consultant for a legal proceeding
- Channa Kolb, MD,
(1) Teva (2) EMD Serono (3) Novartis (3) Biogen
NONE
(1) Teva (2) EMD Serono (3) Biogen (4) Novartis (4) Mallinkrodt
NONE
NONE
NONE
NONE
NONE
(1) Teva (2) EMD Serono (3) Biogen (4) Novartis (5) Mallinkrodt
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Bianca Weinstock-Guttman, MD and
National Multiple Sclerosis Society, Medical Advisory Board, 2006-Present
NONE
NONE
NONE
NONE
NONE
NONE
Advisory board for :Biogen, EMDSerono, Novartis, Genentech, Mallinckrodt
Biogen & Idec;TEVA Neuroscience, EMD Serono, Genzyme
NONE
NONE
research grants from Biogen Idec, EMD Serono, TEVA, Novartis, Genentech, Mallickrodt
NIH multicenter studiesNMSS
NONE
National MS Society, Clinical grant for Pediatric MS
NONE
NONE
NONE
NONE
NONE
NONE
- David Hojnacki, MD
NONE
NONE
Biogen, Genentech, EMD Serono, Novartis
NONE
NONE
NONE
NONE
(1) Biogen (2) EMD Serono (3) Novartis (4) Genentech
(1) Biogen (2) EMD Serono (3) Novartis (4) Genentech
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Buffalo Neuroimaging Analysis Center (R.Z., N.B., J.H., D.P.R.) and Jacobs Comprehensive MS Treatment and Research Center (C.K., B.W.-G., D.H.), Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, and Center for Biomedical Imaging at Clinical Translational Science Institute (R.Z., M.G.D., F.S.), University at Buffalo, State University of New York.
- Correspondence
Dr. Zivadinov rzivadinov{at}bnac.net
Article usage
Cited By...
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.